Drug search by name

Pasireotide Subcutaneous and Diabetes

Result of checking the interaction of drug Pasireotide Subcutaneous and disease Diabetes for safety when used together.

Check result:

Pasireotide Subcutaneous <> Diabetes

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Elevations in blood glucose levels have been reported with the use of somatostatin analogs. Cushing's disease patients with poor glycemic control may be at a higher risk of developing severe hyperglycemia and associated complications, e.g., ketoacidosis. It is recommended to assess the glycemic status of hemoglobin A1C prior to starting treatment with these agents. Self-monitoring of blood glucose and/or FPG assessments should be done every week for the first two to three months and periodically thereafter, as clinically appropriate, as well as over the first two to four weeks after any dose increase. If uncontrolled hyperglycemia persists, despite appropriate medical management, the dose of these agents should be reduced or discontinued.

Pasireotide Subcutaneous

Generic Name: pasireotide

Brand Name: Signifor, Signifor LAR

Synonyms: Pasireotide

What is Pasireotide Subcutaneous?